SCHEMBL276918

SCHEMBL276918

[O]c1nncc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ TP53 P04637 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ GOT1 P17174 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ MPO P05164 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2D6 P10635 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ MAOA P21397 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ THPO P40225 1/20 0.52
▸ AOX1 Q06278 1/20 0.52
▸ ACOX1 Q15067 1/20 0.52
▸ TDP1 Q9NUW8 3/20 0.50
▸ MAPT P10636 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30523852 0.76 KDM4E (0.55) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL1673296 0.76 KDM4E (0.55) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL17295055 0.74 NPC1 (0.53) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL3682512 0.74 NPC1 (0.48) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL4043088 0.73 KDM4E (0.52) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL147684 0.73 KDM4E (0.52) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL291004 0.73 LMNA (0.52) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL600018 0.73 KDM4E (0.57) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL18630480 0.73 KDM4E (0.52) LMNAKDM4EALDH1A1TP53CYP3A4
SCHEMBL4043089 0.73 KDM4E (0.52) LMNAKDM4EALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 — — CN disclosed
EP-4214200-A1 LANCL LIGANDS Nimmune Biopharma, Inc. (US) 2023-07-26 — — EP disclosed
CN-113748109-B Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands 朗多生物制药股份有限公司 2023-07-21 — — CN disclosed
CN-116368133-A NLRX1 ligand 朗多生物制药股份有限公司 2023-06-30 — — CN disclosed
US-20230167083-A1 LANCL LIGANDS LANDOS BIOPHARMA, INC. (US) 2023-06-01 — — US disclosed
US-20230133149-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-05-04 — — US disclosed
US-20230126543-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-04-27 — — US disclosed
CN-115485272-A PLXDC2 ligands 朗多生物制药股份有限公司 2022-12-16 — — CN disclosed
US-11459310-B2 LANCL ligands LANDOS BIOPHARMA, INC. (US) 2022-10-04 — — US disclosed
US-20220204453-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE SAMSUNG ELECTRONICS CO., LTD. (KR) 2022-06-30 — — US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 — — EP disclosed
US-20060009439-A1 Novel physiologically active substances MERCIAN CORPORATION (JP) 2006-01-12 — — US disclosed
WO-2005082892-A2 TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-09-09 — — WO disclosed
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof DR. REDDY'S LABORATORIES LTD. (IN) 2005-06-02 — — US disclosed
WO-2005042712-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS, INC. (US) 2005-05-12 — — WO disclosed
WO-2005040163-A1 HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) DR. REDDY'S LABORATORIES LTD (IN) 2005-05-06 — — WO disclosed
WO-2005040104-A1 NOVEL COMPOUNDS AND THEIR USE IN MEDICINE: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-05-06 — — WO disclosed
WO-2005035528-A2 TRIAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS DR. REDDY'S LABORATORIES LTD. (IN) 2005-04-21 — — WO disclosed
EP-1508570-A1 NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES MERCIAN CORPORATION (JP) 2005-02-23 — — EP disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133149-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP2E1, ORC3 LMNA 2845/4885KDM4E 2206/4885ALDH1A1 59/4885
US-20060009439-A1 Novel physiologically active substances HIF1A, HIF1AN, VEGFA LMNA 4726/4885KDM4E 3533/4885ALDH1A1 108/4885
US-11459310-B2 LANCL ligands LANCL2, LANCL1, ACSL1 LMNA 826/4885KDM4E 3796/4885ALDH1A1 3541/4885
US-20230126543-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, AOX1, CRY1 LMNA 2925/4885KDM4E 2983/4885ALDH1A1 12/4885
US-20220204453-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP2E1, CYP1A2 LMNA 2680/4885KDM4E 3115/4885ALDH1A1 49/4885
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof PYGM, MYLK, HMOX1 LMNA 328/4885KDM4E 1840/4885ALDH1A1 1460/4885
US-20230167083-A1 LANCL LIGANDS LANCL2, LANCL1, LCLAT1 LMNA 1134/4885KDM4E 3554/4885ALDH1A1 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback